Cepheid Advances Innovation & Reach with Key Partnerships

At Danaher, innovation moves at the speed of life—but we know we can’t do it alone. Across the globe, Cepheid’s partners play a vital role in helping us bring breakthrough technologies and innovation to life and deliver our products to more people around the world.  In this article, discover how our partners are helping us accelerate innovation, scale our reach, and transform the future of diagnostics. Together, we’re not just advancing science, we’re changing the world.

Oxford Nanopore Technologies - April 2025

Oxford Nanopore Technologies and Cepheid announced a strategic collaboration to develop and commercialize a seamless end-to-end workflow that combines Cepheid's GeneXpert system for pre-sequencing sample and library preparation with Oxford Nanopore's fast, information-rich molecular analysis platform.

The initial application will focus on infectious disease, specifically the profiling of bacterial and fungal pathogens with whole genome sequencing, first from culture isolates and eventually directly from positive blood cultures. The collaboration has the potential to expand from infectious disease use cases to cancer and human genetics and eventually regulatory-approved clinical diagnostics. Watch the video to learn more:

Fleming Initiative - September 2024

Cepheid announced a groundbreaking partnership with the Fleming Initiative during the 2024 UNGA meeting on antimicrobial resistance (AMR) in New York City, becoming the first diagnostics company to join this global collaboration led by Imperial College Healthcare NHS Trust and Imperial College London. This alliance brings together research, behavior change, public engagement, and policy to combat AMR through expanded use of in vitro diagnostics, early infection screening, decentralized care for respiratory infections, and a precision medicine approach to sepsis—driving real-world solutions and global action against one of the most urgent health threats of our time.

Oxford University - November 2023

Danaher partnered with the University of Oxford to develop a fast molecular diagnostic test for sepsis, leveraging research from Professor Julian Knight and technology from Cepheid. This collaboration, part of Danaher’s Beacons program—which funds pioneering academic research aimed at product innovation—focuses on enabling precision medicine by identifying sepsis subtypes through RNA-based immune profiling. The sepsis subtyping test, designed to deliver results within an hour, could help clinicians tailor therapies, improve patient outcomes, and support smarter clinical trial design with up to 4 potential clinical uses:

• Prognostic of sepsis outcomes
• Predictive of immunomodulatory therapy treatment response
• Monitor response to treatment
• Screen at-risk patients for early sepsis detection

The partnership exemplifies the Beacons program’s mission to translate cutting-edge science into real-world health solutions. Focus areas include genomic medicines, precision diagnostics, and data sciences.

Global Access Program - Global Fund - September 2023

In 2023, Danaher announced it would provide Cepheid’s Xpert® MTB/RIF Ultra tuberculosis (TB) test cartridges for TB at cost to the Global Fund and eligible low- and middle-income countries through its Global Access Program. This initiative, supported by annual third-party cost assessments, aims to expand access to high-quality TB diagnostics. For over 15 years, Cepheid has worked to improve testing availability in regions with high TB and infectious disease burdens. By offering more accurate and affordable tests, Danaher and Cepheid are helping to improve health outcomes and save lives in communities that need it most.